Education
About Us
Working with TipRanks
Follow Us
Cellectar Biosciences (CLRB)
NASDAQ:CLRB
Earnings Data
Report Date
Mar 18, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-1.22Last Year’s EPS
-2.1Same Quarter Last Year
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted significant regulatory advancements for iopofosine I-131, a strengthened financial position, and positive clinical developments. However, there are concerns about decreased cash reserves and the need for additional funding to proceed with key US trials. Overall, the achievements and progress in regulatory and clinical areas outweigh the challenges, indicating a positive outlook.Company Guidance
Regulatory Advancements for Iopofosine I-131
Received confirmation of eligibility to file for conditional marketing approval in the EU based on the Clover Wham study, with an 80% chance of success. Also planning to submit an NDA for accelerated approval in the US.
Financial Position Strengthened
Raised approximately $12.7 million in recent financings, with a strong balance sheet expected to fund operations into the third quarter of 2026.
Positive Clinical Developments
Initiation of phase 1b study of CLR125 for triple-negative breast cancer and CLR225 targeting pancreatic cancer. Positive data showcased at major conferences.
Reduced Expenses and Net Loss
Research and development expenses decreased to $2.5 million from $5.5 million, and general and administrative expenses decreased to $2.3 million from $7.8 million year-over-year. Net loss reduced to $4.4 million from $14.7 million.
CLRB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CLRB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 13, 2025 | $3.50 | $2.87 | -18.00% |
Aug 14, 2025 | $4.42 | $4.42 | 0.00% |
May 13, 2025 | $7.92 | $7.20 | -9.09% |
Mar 13, 2025 | $9.50 | $8.99 | -5.37% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cellectar Biosciences (CLRB) report earnings?
Cellectar Biosciences (CLRB) is schdueled to report earning on Mar 18, 2026, TBA (Confirmed).
What is Cellectar Biosciences (CLRB) earnings time?
Cellectar Biosciences (CLRB) earnings time is at Mar 18, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CLRB EPS forecast?
CLRB EPS forecast for the fiscal quarter 2025 (Q4) is -1.22.